Drug Trial Radar · NCT05612035
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
129
Actual
Start
Mar 16, 2023
Primary completion
Apr 9, 2026
Study completion May 1, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Conditions
- Pulmonary Hypertension
- Chronic Obstructive Pulmonary Disease
Interventions
FrespaciguatDrug
Frespaciguat 380 µg administered as dry powder inhalation once daily.
PlaceboDrug
Placebo administered as dry powder inhalation once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in 6-minute Walk Distance (6MWD) at Week 24Time frame: Baseline and Week 24
Locations
85 sites in 19 countries. Site status is shown where the registry gives one.
UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110)
San Francisco, California
University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 0101)
Aurora, Colorado
Clinovation Intl. Corp. ( Site 0108)
Sebring, Florida
Alexian Brothers Medical Center-Pulmonary ( Site 0109)
Elk Grove Village, Illinois
University of Iowa ( Site 0103)
Iowa City, Iowa
University of Kansas Medical Center-IM-Pulmonary and Critical Care Medicine ( Site 0102)
Kansas City, Kansas
Lexington VA Medical Center - Cooper Division ( Site 0137)
Lexington, Kentucky
Corewell Health ( Site 0133)
Grand Rapids, Michigan
Mayo Clinic in Rochester, Minnesota ( Site 0131)
Rochester, Minnesota
Creighton University Clinical Research Office ( Site 0123)
Omaha, Nebraska
University of New Mexico Hospital ( Site 0146)
Albuquerque, New Mexico
UNC Health - Eastowne Medical Office-Clinical Trials Unit ( Site 0147)
Chapel Hill, North Carolina
Temple University Hospital ( Site 0104)
Philadelphia, Pennsylvania
UPMC Montefiore University Hospital-Department of Medicine ( Site 0149)
Pittsburgh, Pennsylvania
UT Southwestern Medical Center ( Site 0114)
Dallas, Texas
The University of Texas Health Science Center at Houston ( Site 0105)
Houston, Texas
Intermountain Medical Center-Division of Pulmonary & Critical Care Medicine ( Site 0140)
Murray, Utah
University of Virginia Health System-Division of Pulmonary and Critical Care Medicine ( Site 0111)
Charlottesville, Virginia
Hospital Britanico de Buenos Aires ( Site 0307)
CABA, Argentina
Hospital Privado Universitario de Córdoba-Clinical Cardiology Department ( Site 0302)
Córdoba, Argentina
Fundación Respirar ( Site 0305)
CABA, Buenos Aires, Argentina
Centro Medico Capital ( Site 0301)
La Plata, Buenos Aires, Argentina
Instituto de Cardiologia de Tucuman-Area de Investigacion Clinica ( Site 0303)
San Miguel de Tucumán, Tucumán Province, Argentina
Royal Prince Alfred Hospital-Department of Respiratory Medicine ( Site 0903)
Camperdown, New South Wales, Australia
Westmead Hospital ( Site 0902)
Westmead, New South Wales, Australia
WESLEY RESEARCH INSTITUTE Limited ( Site 0906)
Auchenflower, Queensland, Australia
The Prince Charles Hospital ( Site 0904)
Brisbane, Queensland, Australia
Mater Misericordiae Limited ( Site 0905)
South Brisbane, Queensland, Australia
Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 1201)
Graz, Styria, Austria
Medizinische Universitaet Innsbruck ( Site 1202)
Innsbruck, Tyrol, Austria
Université Libre de Bruxelles - Hôpital Erasme ( Site 1302)
Brussels, Bruxelles-Capitale, Region de, Belgium
UZ Leuven ( Site 1301)
Leuven, Vlaams-Brabant, Belgium
Clinica Cardio VID ( Site 0504)
Medellín, Antioquia, Colombia
Ciensalud Ips S A S ( Site 0508)
Barranquilla, Atlántico, Colombia
Fundación Valle del Lili ( Site 0509)
Cali, Valle del Cauca Department, Colombia
Centro de Investigaciones Clinicas SAS ( Site 0505)
Cali, Valle del Cauca Department, Colombia
C.H.U Hôpital Nord ( Site 1503)
Marseille, Bouches-du-Rhone, France
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois ( Site 1502)
Vandœuvre-lès-Nancy, Lorraine, France
CHU Angers ( Site 1506)
Angers, Maine-et-Loire, France
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre-Pneumologie ( Site 1501)
Le Kremlin-Bicêtre, Paris, France
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.